Sanofi Tells 3rd Circ. Post-Ch. 11 Drug Sales Triggered Deal

By Matthew Santoni (December 11, 2023, 3:59 PM EST) -- Sales of a drug that a Mallinckrodt PLC unit bought the rights for prior to its 2020 Chapter 11 bankruptcy should still trigger an obligation to pay the drug's originator royalties, since the deal allegedly survived the reorganization, an attorney for Sanofi Aventis told the Third Circuit on Monday....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!